Saniona AB (publ) (FRA:30S)

Market Cap	321.87M +317.3%
Revenue (ttm)	67.22M +2,687.5%
Net Income	51.87M
EPS	0.41
Shares Out	n/a
PE Ratio	6.21
Forward PE	11.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	54
Open	2.275
Previous Close	2.315
Day's Range	2.275 - 2.275
52-Week Range	0.480 - 2.575
Beta	n/a
RSI	50.45
Earnings Date	Feb 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Pharmaceutical Preparations
• Founded: 2011
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30S

Financial Performance

Financial numbers in SEK